Montrouge, France

Alexandre Mebazza

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Assistance Publique-Hopitaux De Paris, Université Paris Diderot-Paris 7. Active years: 2020.


% Patents Active = 100.0


 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Alexandre Mebazza

Introduction

Alexandre Mebazza is a notable inventor based in Montrouge, France. He has made significant contributions to the field of cardiovascular resuscitation through his innovative methods and research. His work focuses on improving patient outcomes by enhancing monitoring techniques for at-risk individuals.

Latest Patents

Mebazza holds a patent for a method titled "Method for the continuous evaluation of the ventriculo-aortic coupling of at-risk patients by analysis of pressure-flow loops." This invention relates to the monitoring of ventriculo-aortic coupling based on the aortic pressure/flow loop of patients. It aims to provide a novel approach to assessing cardiovascular health in critical situations.

Career Highlights

Throughout his career, Mebazza has been associated with prestigious institutions such as Université Paris Diderot-Paris 7 and Assistance Publique-Hôpitaux de Paris. His work in these organizations has allowed him to collaborate with leading experts in the field and contribute to advancements in medical technology.

Collaborations

Mebazza has worked alongside notable colleagues, including Fabrice Vallee and Arthur Le Gall. Their combined expertise has fostered a collaborative environment that promotes innovation in cardiovascular research.

Conclusion

Alexandre Mebazza's contributions to cardiovascular resuscitation through his patented methods highlight his commitment to improving patient care. His work continues to influence the medical field and inspire future innovations.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…